logo

XTNT

Xtant Medical·AMEX
--
--(--)
--
--(--)
1.81 / 10
Underperform

Fundamental analysis shows XTNT with a low 1.8/10 score. Strengths lie in Asset-MV and Cash-MV factors, yet significant weaknesses are evident in Net income-Revenue and Revenue-MV. Metrics like ROA and net profit margin are subpar, and the interest coverage ratio is only 2.83, indicating limited financial resilience. Overall, the fundamental picture is unfavorable for investment.

Fundamental(1.81)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value0.62
Score1/3
Weight19.60%
1M Return-1.83%
ROA (%)
Value4.91
Score1/3
Weight7.18%
1M Return-0.54%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight19.80%
1M Return-1.71%
Net income-Revenue
Value-1.53
Score1/3
Weight27.95%
1M Return-2.55%
Cash-UP
Value0.66
Score2/3
Weight48.27%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value6.55
Score1/3
Weight7.18%
1M Return-0.54%
Interest coverage ratio (EBIT / Interest expense) (%)
Value2.83
Score2/3
Weight22.32%
1M Return-1.95%
Asset-MV
Value-0.50
Score2/3
Weight-23.23%
1M Return1.60%
Cash-MV
Value0.06
Score2/3
Weight-49.87%
1M Return3.31%
Net profit / Total profit (%)
Value90.99
Score2/3
Weight20.79%
1M Return-1.71%
Is XTNT fundamentally strong?
  • XTNT scores 1.81/10 on fundamentals and holds a Premium valuation at present. Backed by its 10.53% ROE, 1.32% net margin, -18.08 P/E ratio, 1.64 P/B ratio, and 115.38% earnings growth, these metrics solidify its Underperform investment rating.